论文部分内容阅读
有人报告在小鼠实验中,肿瘤内浸润淋巴细胞(TIL)与患癌鼠脾淋巴细胞诱导的LAK 细胞相比,对自身肿瘤细胞毒性高50～100倍。现已了解到,即使从人类实体瘤分离出来的TIL 对自身肿瘤也具有较强的细胞毒性。然而,在临床上由肺癌患者分离TIL还有很多困难,因此用于被动免疫疗法的病例还很少。肺癌患者多数伴有癌性胸膜炎,在胸水中渗出的淋巴细胞(PLEL)与肿瘤细胞并存,这种淋巴细胞对肿瘤较敏感,而且易于采取。以对自身肿瘤的细胞毒性为指标,将PLEL 与末梢血淋巴细胞(PBL)在培养前
It has been reported that in mouse experiments, tumor-infiltrating lymphocytes (TIL) are 50-100 times more toxic to autologous tumor cells than LAK cells induced by splenic lymphocytes from cancerous mice. It has been learned that even the TIL isolated from human solid tumors has strong cytotoxicity to autologous tumors. However, there are still many difficulties in the clinical separation of TIL from lung cancer patients, so there are few cases for passive immunotherapy. The majority of lung cancer patients are accompanied by cancerous pleuritis. Peritoneal lymphocytes (PLEL) and tumor cells co-exist in the pleural effusion. This lymphocyte is more sensitive to tumors and can be easily taken. The PLXL and peripheral blood lymphocytes (PBL) were pre-cultured using the cytotoxicity of the autologous tumor as an indicator